



UNIVERSITI PUTRA MALAYSIA

***ANTI-HYPERTENSIVE EFFECT OF PROTEOLYSATE GENERATED
FROM STONE FISH (ACTINOPYGA LECANORA JAEGER) IN RATS***

MAHDOKHT SADEGH VISHKAEI

FSTM 2015 7



**ANTI-HYPERTENSIVE EFFECT OF PROTEOLYSATE GENERATED FROM
STONE FISH (*ACTINOPYGA LECANORA* JAEGER) IN RATS**

By

MAHDOKHT SADEGH VISHKAEI

**Thesis Submitted to the School of Graduate Studies, University Putra Malaysia in
Fulfilment of the Requirement for the Degree of Master of science**

April 2015

COPYRIGHT

All materials contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



DEDICATION

To my mom, the bravest woman I have ever seen who beat cancer lonely with her smile when I was doing my master in Malaysia. I give my deepest expression of apologise for not being with you. All that I am I owe to your endless sacrifice, true and unwavering love and sincere support from the moment I was born until now. Hoping my quest to get this degree of higher education is making your dream a reality.

To my father, who earns an honest living for us. I give my deepest expression of love and appreciation for all the sacrifices you have made during my life and study and for your sincere and unconditional supports. I am honored to have you as my father.

To my sister Bitu, who always takes care of me from the time I was born until now for sharing laughter and wiping tears and for all the sacrifices that you have made to all our family members. Side by side or miles apart, we are connected by heart.

© COPYRIGHT UPM



Abstract of thesis presented to the Senate of Universiti Putra Malaysian in fulfillment of the requirement for the degree of Master of Science

ANTI-HYPERTENSIVE EFFECT OF PROTEOLYSATE GENERATED FROM STONE FISH (*ACTINOPYGA LECANORA JAEGER*) IN RATS

By

MAHDOKHT SADEGHVISHKAEI

April 2015

Chairman: Prof Nazamid Saari, PhD
Faculty: Food Science and Technology

Bioactive peptides within the original food-derived proteins are short sequences of amino acids that are inactive in the sequence of the parent protein. However, they can be activated through different ways including enzymatic hydrolysis. Among all the bioactive peptides, antihypertensive bioactive peptides are considered as a vitally important peptides since they are able to function as Angiotensin converting enzyme (ACE) inhibitors and have effective role in curing hypertension which is a common and serious chronic health problem and known as the most important risk factor for development of many diseases such as stroke. The ACE inhibitory effect of *Actinopyga lecanora* proteolysate *in vitro* had been reported. Hence, this study aimed to evaluate the ACE inhibitory potential of *A. lecanora* proteolysate *in vivo* (in normotensive rats). In this regard, the ACE inhibitory capability of the proteolysate to prevent increasing blood pressure, after inducing hypertension by angiotensin I was examined in normal rats. The pre-fed rats with the proteolysates at various doses (200, 400, 800 mg/kg body weight) revealed the significant ($p \leq 0.05$) suppression effect compared with control groups after inducing hypertension. Furthermore, different doses of the proteolysate (200, 400, 800 mg/kg body weight) were examined to decrease the blood pressure of hypertension-induced rats. Results depicted that 800 mg proteolysate/kg body weight significantly reduced blood pressure without a negative effect on normal blood pressure ($p \leq 0.05$). Sub-acute toxicity study based on OECD guideline demonstrated no toxicity effect of the proteolysate *in vivo*. The present study indicated that the proteolysate at a dose of 1000 mg/kg daily did not cause toxicity signs such as death, changes in activity, or piloerection. Since there are no significant differences between treated groups and control groups, hematological and biochemical analysis confirmed the safety of the proteolysate ($p > 0.05$). In addition, there were no significant differences between organs weights of the treated groups and the control groups. Morphologically, neither histopathological changes nor gross abnormalities were observed. However, the proteolysate caused a significant decrease in body weight in relation to the control groups ($p \leq 0.05$) probably due to appetite stimulation by the proteolysate, leading to decreased food consumption in the sub-acute group. It is concluded that the proteolysate generated from *A. lecanora* possess a significant *anti-hypertensive* effect and would be potentially used as a natural alternative of ACE inhibitors.

Abstrak tesis ini dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk Ijazah Sarjana Sains

Kesan anti -hipertensi proteolisat daripada ikan batu (*Actinopyga lecanora*) ke atas tikus

Oleh

Mahdokht Sadegh Vishkaei

April 2015

Pengerusi: Prof. Nazamid Saari, PhD
Fakulti: Sains dan Teknologi Makanan

Peptida bioaktif dalam protein makanan adalah jujukan pendek asid amino yang tidak aktif dalam jujukan protein induk. Walau bagaimanapun, mereka boleh diaktifkan melalui pelbagai cara termasuk hidrolisis enzim. Antara semua peptida bioaktif, peptida bioaktif anti-hipertensi dianggap sebagai peptida yang amat penting kerana mereka dapat berfungsi sebagai perencat kepada enzim penukar angiotensin (ACE) dan seterusnya boleh berperanan secara berkesan mengawal tekanan darah tinggi yang merupakan masalah kesihatan yang meluas dan kronik. Hipertensi turut dikenali sebagai faktor risiko yang paling penting menyebabkan pelbagai penyakit seperti strok. Kesan proteolisat *Actinopyga lecanora* ke atas perencatan ACE dalam kajian *in vitro* telah dilaporkan. Oleh itu, kajian ini bertujuan untuk menilai potensi proteolisat *A. lecanora* sebagai perencat ACE secara *in vivo* menggunakan tikus normotensif. Dalam hal ini, keupayaan perencatan ACE oleh proteolisat untuk mengekang peningkatan tekanan darah telah diperiksa pada tikus normal, selepas hipertensi didorong menggunakan angiotensin 1. Tikus pra -makan dengan proteolisat pada pelbagai dos (200, 400, 800 mg / kg berat badan) menunjukkan kesan pengekanan yang ketara ($p \leq 0.05$) berbanding dengan kumpulan tikus kawalan selepas tekanan darah tinggi didorong. Dos proteolisat pada kepekatan yang berbeza (200, 400, 800 mg/kg berat badan) telah diperiksa untuk mengurangkan tekanan darah tikus hipertensi. Keputusan menunjukkan bahawa penggunaan 800 mg proteolisat/kg berat badan menurunkan tekanan darah tanpa kesan negatif ke atas tekanan darah yang normal ($p \leq 0.05$). Kajian ketoksikan sub-akut berdasarkan garis panduan OECD menunjukkan tiada kesan ketoksikan proteolisat dalam *in vivo*. Kajian ini menunjukkan bahawa proteolisat pada kadar dos 1000 mg/kg berat badan setiap hari tidak menyebabkan tanda-tanda keracunan seperti kematian, perubahan dalam aktiviti, atau piloereksi. Oleh kerana tidak ada perbezaan yang signifikan di antara kumpulan rawatan dan kumpulan kawalan, hematologi dan analisis biokimia mengesahkan keselamatan penggunaan proteolisat ($p > 0.05$). Selain itu, tidak terdapat perbezaan yang ketara di antara berat organ-organ kumpulan yang dirawat dan berat organ-organ kumpulan kawalan. Secara

morfologi, tiada perubahan histopatologi mahupun keabnormalan kasar diperhatikan. Walau bagaimanapun, proteolisat menyebabkan penurunan yang ketara dalam berat badan kumpulan tikus kawalan ($p \leq 0.05$) adalah kemungkinan disebabkan oleh rangsangan selera makan dengan proteolisat yang membawa kepada penurunan pengambilan makanan dalam kumpulan sub-akut. Kajian ini dapat disimpulkan bahawa proteolisat yang dihasilkan dari *A. lecanora* mempunyai kesan anti-hipertensi yang ketara dan berpotensi digunakan sebagai perencat semulajadi alternatif kepada ACE.



ACKNOWLEDGEMENTS

First and foremost, I would like to express my gratitude and appreciation to my supervisor Professor Dr. Nazamid Saari for providing his invaluable advice, constant guidance and encouragement to accomplish this dissertation. His honest advice, patience, thorough guidance and calm demeanor has steered my research toward success.

I would also like to express my sincere thanks and appreciation to my co-supervisor Professor Dr. Azizah Hamid and Professor Dr. Amin Ismail for their constructive instructions, proper guidance and motivation throughout my study period.

Getting through my dissertation required more than academic support, I have many, many people to thank for listening to and, at times, having to tolerate me over the past three years. Most importantly, none of this could have happened without my family. I have no words to express gratitude to them. My mother who always believed in me and encouraged me to obtain higher education, for all the special little things she did for us and my father who always support me mentally and financially without whom this effort would have been worth nothing. Their love, support and constant patience have taught me so much about sacrifice, discipline and compromise. My eldest sisters, Bitra and Mahta for all the time that we share through happiness and sadness and their friendship, caring, endless love, financially and mentally supporting, never-ending guidance and encouragements from the time that I was born until now, and my brother Babak for his friendship and support. Nothing you all have done has been forgotten and day by day you mean more to me. This dissertation stands as a testament to your unconditional love and encouragement. I would also like to thank my cousin Soroor Davoodi and her mother for their end-less support and love during my study.

I cannot begin to express my gratitude and appreciation to my friends for their sincere supports. A lot of thanks to Behzad Shahizare for sharing in my triumphs and tears, his endless patient and support in addition to uncountable helping throughout my lab work and writing thesis, without whom this thesis would not have been written. Many thanks to my dearest, Homa Ebrahimpour for her sincere and never-ending friendship, love, encouragement and support from far away. Simin Hedayatnia has been unwavering in her personal and professional support during the time I spent at the University and I must thank her for her true friendship and many memorable moments in addition to all difficult moments that she was with me and a lot of thanks to Maryam Hazeri for her true friendship and support during my living in Malaysia. I would also like to thank Mahnaz Fallahi who opened both her home and heart to me when I first arrived in Malaysia. I would also like to thank my kind lab-mate Raheleh Ghanbari for her friendly encouragement in assisting and teaching me through lab work.

Thanks to Agro-biotechnology Institute for providing me CODA machine and many thanks to Mr. Ramly and all staffs of animal house in Faculty of Medicine and Health Science for helping and providing me room, cages and other facilities during animal

study and many thanks to my entire lab-mate and friends who were sharing me many unforgettable moments.



This Thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the supervisory committee were as follows:

Nazamid Saari, PhD

Professor
Faculty of Food Science and Technology
University Putra Malaysia
(Chairperson)

Azizah Hamid, PhD

Professor
Faculty of Food Science and Technology
University Putra Malaysia
(Member)

Amin Ismail, PhD

Professor
Faculty of Medicine and Health Science
University Putra Malaysia
(Member)

BUJANG KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by Graduate Student:

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- There is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____ Date: _____

Name and Matric No: Mahdokht Sadegh Vishkaei

Declaration by Member of Supervisory Committee

This is to confirm that:

- The research conducted and the writing of the thesis was under our supervision;
- Supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____

Name of
Chairman of
Supervisory
Committee: Nazamid Saari, PhD

Signature: _____

Name of
Member of
Supervisory
Committee: Azizah Hamid, PhD

Signature: _____

Name of
Member of
Supervisory
Committee: Amin Ismail, PhD

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	ii
ACKNOWLEDGEMENTS	iv
APPROVAL	vi
DECLARATION	vii
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF ABBREVIATIONS	xvi
CHAPTER	
1 INTRODUCTION	1
2 LITERATURE REVIEW	3
2.1 Bioactive Peptides	3
2.1.1 Definition	3
2.2 Food Sources of Bioactive Peptides	4
2.3 Marine Source	7
2.3.1 Sea Cucumber	7
2.3.1.1 Classification	7
2.3.1.2 Sea Cucumber as a Food	9
2.3.1.3 Sea Cucumber and Human Health	9
2.3.1.4 Sea Cucumber Proteins	10
2.4 Health Benefits of Bioactive Peptides	10
2.4.1 Anti-Hypertensive Bioactive Peptides	10
2.5 Angiotensin Converting Enzyme (ACE)	14
2.5.1 Renin Angiotensin System	16
2.5.2 Angiotensin Converting Enzyme Inhibitory Peptides	17
2.6 Hypertension	19
2.6.1 Definition	19
2.6.2 Role of Angiotensin Converting Enzyme in Hypertension	21
2.6.3 Effect of Bioactive Peptides on Hypertension	21
2.7 <i>In vivo</i> Study in Rats	22
2.7.1 Effect of Bioactive Peptides on Hypertension in Rats	22
2.8 Toxicity Study	23
3 MATERIAL AND METHODS	25
3.1 Materials	25
3.2 Hydrolysis	26
3.3 Acclimatization of the Rats	26
3.4 Research Design	27
3.5 Measurement of Blood Pressure in Rats	28

3.5.1	Effect of Proteolysate on ACE in Preventive Group	30
3.5.2	Effect of Proteolysate on High Blood Pressure in Treatment Group	30
3.6	Safety Evaluation	31
3.6.1	Haematological and Biochemical Analysis	31
3.6.2	Morphological Study	33
3.7	Data Analysis	33
4	RESULTS AND DISCUSSION	34
4.1	Preliminary Study	34
4.2	Effect of Proteolysate on Normal Blood Pressure	35
4.3	Preventive Group	37
4.3.1	Effect of Pre-fed Proteolysate on Systolic Blood Pressure	37
4.3.2	Effect of Proteolysate on Diastolic Blood Pressure	38
4.3.3	Effect of Proteolysate to Prevent Increasing Blood Pressure after Inducing Hypertension	39
4.4	Treatment Group	42
4.4.1	Effect of Proteolysate on Systolic Blood Pressure after Inducing Hypertension	42
4.4.2	Effect of Proteolysate on Diastolic Blood Pressure after Inducing Hypertension	44
4.4.3	Curative potential of proteolysate	44
4.5	Heart Rate	46
4.6	Safety Evaluation	47
4.6.1	Sub-acute Toxicity	47
4.6.1.1	Effect of Proteolysate on Body Weight of Rats	48
4.6.1.2	Effect of Proteolysate on Weight of Organs	49
4.6.1.3	Effect of Proteolysate on Haematological Parameters	51
4.6.1.4	Effect of Proteolysate on Biochemical Parameters	51
4.6.1.5	Effect of Proteolysate on Morphological Parameters	53
4.6.2	Satellite Group for Sub-acute Toxicity	57
4.6.2.1	Effect of Proteolysate on Body Weight of Rats	57
4.6.2.2	Effect of Proteolysate on Weight of Organs	58
4.6.2.3	Effect of Proteolysate on Haematological Parameters	59
4.6.2.4	Effect of Proteolysate on Biochemical Parameters	60
4.6.2.5	Effect of Proteolysate on Morphological Parameters	61
5	SUMMARY, CONCLUSION AND RECOMMENDATION FOR FUTURE RESEARCH	65

REFERENCES	67
APPENDICES	86
BIODATA OF STUDENT	90
LIST OF PUBLICATIONS	91

LIST OF TABLES

Table	page
2.1 Food sources of bioactive peptides	5
2.2 Hypotensive effect of ACE protein hydrolysates and peptides in animals	12
2.3 Classification of Hypertension	20
3.1 Animal feed specification	25
4.1 Changes in systolic blood pressure at various time in normotensive rats	34
4.2 Changes in systolic blood pressure at various time in hypertension-induced rats	35
4.3 Heart rate of Sd rats after administration of the proteolysate before and after inducing hypertension	47
4.4 Hematological parameters of Sd rats treated orally with proteolysate (1000mg/kg body weight) or water for 14 days	51
4.5 Blood biochemical parameters of Sd rats treated with proteolysate for liver function	53
4.6 Hematological parameters of Sd rats in satellite group	60

- 4.7 Blood biochemical parameters of Sd rats for Liver function in satellite group 61

LIST OF FIGURES

Figure	Page
2.1 <i>Actinopyga lecanora</i> commonly known as stone fish	8
2.2 Crystal structure of human testicular ACE with the inhibitor (Lisinopril) molecule bound at the centre of the molecule. The green sphere represents the zinc ion and the red spheres represent the bound chloride ions. I and II: ACE is composed of two parts, C: C-terminal, N: N-terminal, Zn: Zinc, Cl: Chlorine	15
2.3 Renin-angiotensin-aldosterone system	17
3.1 Non-invasive blood pressure machine. A) Infrared Warming Platform, B) Rat Holder with Nose Cone, C) Tail Cuff Kit, D) Standard NIBP System 2 Channel Activation, E) Tail Cuff Kit, F) Warming cover	29
3.2 Automated hematology analyser (Sysmex co, KX-21)	32
3.3 Clinical chemistry analyser (Cobas C 311)	32
4.1 The effect of proteolysate (200, 400, 800 mg/kg body weight) on normal systolic blood pressure. Positive group was given captopril (5 mg/kg body weight). Water control group was given distilled water. A-C indicate significant differences at the confidence level of $p \leq 0.05$ (mean \pm SD, N=5)	36
4.2 The effect of proteolysate (200, 400, 800 mg/kg body weight) on normal diastolic blood pressure. Positive group was given captopril (50 mg/kg body weight). Water control group was	36

given distilled water. A-B indicate significant differences at the confidence level of $p \leq 0.05$ (mean \pm SD, N=5)

- 4.3 Changes in systolic blood pressure induced by the injections of angiotensin I (0.03 $\mu\text{g}/\text{kg}$ body weight) and saline (water control group) of treated rats with different doses of proteolysate (200, 400, 800 mg/kg body weight) and positive group captopril (50 mg/kg body weight) in different levels of experiment. 38
- 4.4 Changes in diastolic blood pressure induced by the intravenous injections of angiotensin I (0.03 $\mu\text{g}/\text{kg}$ body weight) and saline (water group) in treated rats with different doses of proteolysate (200, 400, 800 mg/kg body weight) and positive group captopril (50 mg/kg body weight) in different levels of experiment. 39
- 4.5 The effect of angiotensin I (0.3 $\mu\text{g}/\text{kg}$ body weight) in rats pre-fed with proteolysate (200, 400, 800 mg/kg body weight) approximately 60 min before the injections. The positive group was given captopril (50 mg/kg body weight). A-D indicate significant differences at the confidence level of $p \leq 0.05$ (mean \pm SD, N=5) 41
- 4.6 The effect of angiotensin I (0.3 $\mu\text{g}/\text{kg}$ body weight) rats pre-fed with proteolysate (200, 400, 800 mg/kg body weight) approximately 60 min before the injections. The positive group was given captopril (50 mg/kg body weight). A-C indicate significant differences at the confidence level of $p \leq 0.05$ (mean \pm SD, N=5) 41
- 4.7 Changes in systolic blood pressure induced by the intravenous injections of saline (water control group) and angiotensin I (0.03 $\mu\text{g}/\text{kg}$ body weight) in treated rats with different dose of proteolysate (200, 400, 800 mg/kg body weight) and positive group (captopril 50 mg/kg body weight) in different levels of experiment. 43
- 4.8 Changes in diastolic blood pressure induced by the intravenous injections of angiotensin I (0.03 $\mu\text{g}/\text{kg}$ body weight) and saline (water group) in treated rats with different doses of proteolysate (200, 400, 800 mg/kg body weight) and positive group (captopril 50 mg/kg body weight) in different levels of 44

experiment.

- 4.9 The effect of proteolysate (200, 400, 800 mg/kg body weight) after inducing hypertension by angiotensin I (0.3 mg/kg body weight) in normotensive rats. Positive group was given captopril (50 mg/kg body weight). A-E indicate significant differences at the confidence level of $p \leq 0.05$ (mean \pm SD, N=5). 45
- 4.10 The effect of proteolysate (200, 400, 800 mg/kg body weight) after inducing hypertension by angiotensin I (0.3 μ g/kg body weight) in normotensive rats. Positive group was given captopril (50 mg/kg body weight). A-C indicate significant differences at the confidence level of $p \leq 0.05$ (mean \pm SD, N=5). 46
- 4.11 Body weight gain of Sd rats treated orally with proteolysate (1000mg/kg body weight) or water for 14 days. Bars are means \pm SD for 5 rats/Group. The differences between the control and treated groups were evaluated by Student's *t*-test. 49
- 4.12 Liver weight of Sd rats treated orally with proteolysate (1000mg/kg body weight) or water for 14 days. Bars are means \pm SD for 5 rats/Group. The differences between the control and treated groups were evaluated by Student's *t*-test. 50
- 4.13 Kidney weight of Sd rats treated orally with proteolysate (1000mg/kg body weight) or water for 14 days. Bars are means \pm SD for 5 rats/Group. The differences between the control and treated groups were evaluated by Student's *t*-test. 50
- 4.14 Representative macroscopic findings of the liver and kidney of Sd rats treated orally with proteolysate at dose 1000 mg/kg body weight for 14 days in sub-acute group. 54
- 4.15 Representative microscopic findings in the liver of Sd rats treated orally with proteolysate (Hematoxylin-eosin Stain x40). (a, b and c) control group for sub-acute toxicity showing normal histological structure of central vein (CV), hepatocytes (H) and 55

nucleus (N). (d, e and f) proteolysate group for sub-acute toxicity.

- 4.16 Representative microscopic findings in the kidney of Sd rats treated orally with proteolysate (Hematoxylin-eosin Stain x40). (a, b and c) control group for sub-acute toxicity showing normal histological structure of glomerulus (G), tubules (T). (d, e and f) proteolysate group for sub-acute toxicity. 56
- 4.17 Body weight gain of Sd rats treated orally with proteolysate (1000mg/kg body weight) or water for 14 days followed by no treatment for 14 days. Bars are means \pm SD for 5 rats/Group. The differences between the control and treated groups were evaluated by Student's *t*-test. 57
- 4.18 Liver weight of Sd rats treated orally with proteolysate (1000mg/kg body weight) or water for 14 days followed by no treatment for 14 days. Bars are means \pm SD for 5 rats/Group. The differences between the control and treated groups were evaluated by Student's *t*-test. 58
- 4.19 Kidney weight of Sd rats treated orally with proteolysate (1000mg/kg body weight) or water for 14 days followed by no treatment for 14 days. Bars are means \pm SD for 5 rats/Group. The differences between the control and treated groups were evaluated by Student's *t*-test. 59
- 4.20 Representative macroscopic findings of liver and kidney of Sd rats treated orally with proteolysate at a dose of 1000 mg/kg body weight for 14 days followed by 14 days without treatment in satellite group. 62
- 4.21 Representative microscopic findings in the liver of Sd rats treated orally with proteolysate (Hematoxylin-eosin Stain x40). (a, b and c) control group for satellite toxicity showing normal histological structure of central vein (CV), hepatocytes (H) and nucleus (N). (d, e and f) proteolysate group for satellite toxicity. 63

- 4.22 Representative microscopic findings in the kidney of Sd rats treated orally with proteolysate (Hematoxylin-eosin Stain x40). (a, b and c) control group for satellite toxicity showing normal histological structure of glomerulus (G), tubules (T). (d, e and f) proteolysate group for satellite toxicity. 64

LIST OF ABBREVIATIONS

ACE	Angiotensin I-converting enzyme
GI	Gastrointestinal
CVDs	Cardiovascular diseases
SHR	Spontaneously hypertensive rats
EPA	Eicosapentaenoic acid
DHA	Docosahexaenoic acid
IC ₅₀	The half maximal inhibitory concentration
BP	Blood pressure
HBP	High blood pressure
BPM	Beat per minute
WKS	Weeks
mg	Milligram
kg	Kilogram
bw	Body weight
SBP	Systolic blood pressure
DBP	Diastolic blood pressure

RAS	Renin angiotensin system
Zn	Zinc
TRP	Tryptophan
mmHg	Millimetres of mercury
pH	Hydrogen ion exponent
rpm	Revolution per minute
°C	Degrees celsius
min	Minute
mM	Millimolar
h	Hour
%	Percentage
Sd	Sprague dawley
mL	<i>Millilitre</i>
µg	Microgram
mg	Milligram
OECD	The Organisation for economic co-operation and development
WBC	White blood cell
RBC	Red blood cell
Hgb	Hemoglobin
Hct	Hematocrit
MCV	Mean corpuscular volume

MCHC	Mean corpuscular hemoglobin Concentration
MCH	Mean corpuscular hemoglobin
PLT	Platelet count
BUN	Blood urea nitrogen
AST	Aspartate aminotransferase
ALT	Alanine aminotransferase
ALP	Alkaline phosphatase
P	Probability
SD	Standard deviation
MW	Molecular weight
MWCO	Molecular weight cut off
et al.	And others
ANOVA	Analysis of variance
Da	Dalton
G	Gram
E/S	Enzyme-substrate ratio

CHAPTER 1

INTRODUCTION

Hypertension is a common and critical chronic health problem, and recognized as a most important risk issue for development of numerous diseases including cardiovascular disease (CVD), stroke, arteriosclerosis, as well as myocardial infarction affecting 15–20% of adults throughout the world and estimates more than 1.56 billion of the population worldwide will suffer from hypertension by 2025 (Reiner, 2009; Rampal, Azhar, & Rahman, 2008). In Asian countries, hypertension is actually popular and has effects on public health. (Ahhmed & Muguruma, 2010). In Malaysia, the prevalence of high blood pressure is high, although levels of consciousness, treatment and control are low. Consequently, there is an urgent need for a comprehensive integrated population-based intervention program to improve the rising issue of hypertension throughout Malaysians (Rampal et al., 2008). Nowadays, the effective synthetic ACE inhibitors stabilize blood pressure. However, they do not remove the root cause, which is as yet unknown. Accordingly, in most cases, hypertension is treated non-specifically because it is of unknown type or is diagnosed at an advanced stage (Ahhmed & Muguruma, 2010). Moreover, synthetic ACE inhibitors can have adverse effects such as skin rashes, taste disturbances and cough (Alashi et al., 2014). Therefore, the search for methods which relate to diet and prevent hypertension is markedly of interest with the probability of functional foods. The most well-established mechanism which is based on the blood-pressure-lowering effect is angiotensin-converting enzyme (ACE) activity inhibition.

ACE inhibitors with the source of protein hydrolysate have been acquired from various food (animal sources and plant sources) such as bovine casein (Miguel, Contreras, Recio, & Aleixandre, 2009), fermented foods (Je, Park, Byun, Jung, & Kim, 2005), red algae (Qu et al., 2010). However, just *in vivo* study can certainly confirm that any specific hydrolysate has antihypertensive effect or not, which usually is based on its destiny to come across gastrointestinal (GI) enzymes and brush-border membrane peptidases after administration orally.

Actinopyga lecanora, a kind of sea cucumber which is known as stone fish with moderately high protein substance, was investigated as raw material for the production of bioactive peptides. Due to its comparatively higher protein substance and base on the results of previous study on its *in vitro* ACE inhibitory effect, *A. lecanora* would be a possible source for the generation of bioactive peptides and bromelain generated proteolysate can exhibit a significant anti-hypertensive effect as well as curative effect *in vivo*. As there is no well-established scientific *in vivo* information reported on the antihypertensive activity of proteolysate derived from *A. lecanora*, accordingly this

study aimed to investigate the antihypertensive activity of *A. lecanora* proteolysate *in vivo*. The main research questions were as follows:

- Whether different doses of proteolysate can significantly affect normal blood pressure before inducing hypertension by Angiotensin I?
- Whether different doses of proteolysate can significantly prevent blood pressure to increase? And whether different doses of proteolysate can markedly decrease blood pressure as an alternative therapy?
- Are there any significant differences between different doses of proteolysate?
- Are there any significant differences between the effective dose and anti-hypertensive synthetic drug?
- Whether the proteolysate cause any toxicity for human in the case of consumption?

The current study aimed to evaluate ACE inhibitory potential of *A. lecanora* proteolysate *in vivo* (in normotensive rats). In this regard, the effect of different doses of proteolysate on normal blood pressure were investigated. In addition, the effect of the proteolysate to prevent blood pressure to increase, and the capability of the proteolysate to decrease blood pressure were evaluated. The toxicity study was determined by assessing body weight gain, organs weight, haematological and biochemical parameters, macroscopic and microscopic findings. The main goal of the present work was to investigate an ACE inhibitor proteolysate derived from a marine source with desirable functional characteristics comparable with a synthetic drug for hypertension.

In the current study, the main objectives were as follows:

- To examine the ACE inhibitory capability of the proteolysate to prevent increasing blood pressure in normal rats after inducing hypertension by angiotensin I.
- To examine the capability of the proteolysate to decrease the blood pressure of hypertension-induced rats.
- To determine toxicity of proteolysate in rats using OECD guideline.

REFERENCES

- Ahhmed, A. M., & Muguruma, M. (2010). A review of meat protein hydrolysates and hypertension. *Meat Science*, 86(1), 110-118.
- Alashi, A. M., Blanchard, C. L., Mailer, R. J., Agboola, S. O., Mawson, A. J., He, R., Aluko, R. E. (2014). Blood pressure lowering effects of Australian canolaprotein hydrolysates in spontaneously hypertensive rats. *Food Research International*, 55, 281-287.
- Althunibat, O. Y., Hashim, R. B., Taher, M., Daud, J. M., Ikeda, M.-A., & Zali, B. (2009). In vitro antioxidant and antiproliferative activities of three Malaysian sea cucumber species. *European Journal of Scientific Research*, 37(3), 376-387.
- Aminin, D., Chaykina, E., Agafonova, I., Avilov, S., Kalinin, V., & Stonik, V. (2010). Antitumor activity of the immunomodulatory lead Cumaside. *International Immunopharmacology*, 10(6), 648-654.
- Ariyoshi, Y. (1993). Angiotensin-converting enzyme inhibitors derived from food proteins. *trends in Food Science & technology*, 4(5), 139-144.
- Aydın, M., Sevgili, H., Tufan, B., Emre, Y., & Köse, S. (2011). Proximate composition and fatty acid profile of three different fresh and dried commercial sea cucumbers from Turkey. *International Journal of Food Science & Technology*, 46(3), 500-508.
- Balti, R., Bougatef, A., Guillochon, D., Dhulster, P., Nasri, M., & Nedjar-Arroume, N. (2012). Changes in arterial blood pressure after single oral administration of cuttlefish muscle derived peptides in spontaneously hypertensive rats. *Journal of Functional Foods*, 4(3), 611-617.
- Boerth, R. C., COVELL, J. W., POOL, P. E., & ROSS, J. (1969). Increased myocardial oxygen consumption and contractile state associated with increased heart rate in dogs. *Circulation Research*, 24(5), 725-734.
- Bordenave, S., Fruitier, I., Ballandier, I., Sannier, F., Gildberg, A., Batista, I., & Piot, J.-M. (2002). HPLC preparation of fish waste hydrolysate fractions. Effect on guinea pig ileum and ACE activity. *Preparative Biochemistry and Biotechnology*, 32(1), 65-77.
- Bruckner, A., Johnson, K., & Field, J. (2003). Conservation strategies for sea cucumbers: Can a CITES Appendix II listing promote sustainable international trade. *SPC Beche-De-Mer Information Bulletin*, 18, 24-33.

- Brunner, H. R., Laragh, J. H., Baer, L., Newton, M. A., Goodwin, F. T., Krakoff, L. R., Bühler, F. R. (1972). Essential hypertension: renin and aldosterone, heart attack and stroke. *New England Journal of Medicine*, 286(9), 441-449.
- Byun, H.-G., & Kim, S.-K. (2001). Purification and characterization of angiotensin I converting enzyme (ACE) inhibitory peptides from Alaska pollack skin. *Process Biochemistry*, 36(12), 1155-1162.
- Chen, H.-M., Muramoto, K., Yamauchi, F., Fujimoto, K., & Nokihara, K. (1998). Antioxidative properties of histidine-containing peptides designed from peptide fragments found in the digests of a soybean protein. *Journal of Agricultural and Food Chemistry*, 46(1), 49-53.
- Chen, J. (2003). Overview of sea cucumber farming and sea ranching practices in China. *SPC Bechedemer Information Bulletin*, 18, 18-23.
- Chen, J. R., Okada, t., Muramoto, K., Suetsuna, K., & Yang, S. C. (2002). identification of angiotensin i-converting enzyme inhibitory peptides derived from the peptic digest of soybean protein. *Journal of Food Biochemistry*, 26(6), 543-554.
- Chen, S., Xue, C., Yin, L. a., Tang, Q., Yu, G., & Chai, W. (2011). Comparison of structures and anticoagulant activities of fucosylated chondroitin sulfates from different sea cucumbers. *Carbohydrate Polymers*, 83(2), 688-696
- Cheung, I. W., & Li-Chan, E. C. (2010). Angiotensin-I-converting enzyme inhibitory activity and bitterness of enzymatically-produced hydrolysates of shrimp processing byproducts investigated by Taguchi design. *Food Chemistry*, 122(4), 1003-1012.
- Choi, H., Cho, H., Yang, H., Ra, K., & Suh, H. (2001). Angiotensin I-converting enzyme inhibitor from. *Food Research International*, 34(2), 177-182.
- Daniel, H. (2004). Molecular and integrative physiology of intestinal peptide transport. *Annu. Rev. Physiol.*, 66, 361-384.
- Davalos, A., Miguel, M., Bartolome, B., & Lopez-Fandino, R. (2004). Antioxidant activity of peptides derived from egg white proteins by enzymatic hydrolysis. *Journal of Food Protection*®, 67(9), 1939-1944.

- Du, L., Fang, M., Wu, H., Xie, J., Wu, Y., Li, P., Zhou, L. (2013). A novel angiotensin I-converting enzyme inhibitory peptide from water-soluble protein hydrolysate. *Journal of Functional Foods*, 5(1), 475-483.
- Dziuba, J., Minkiewicz, P., & Nałecz, D. (1999). Biologically active peptides from plant and animal proteins. *Polish Journal of Food and Nutrition Sciences*, 8(1), 3-16.
- Dziuba, J., Minkiewicz, P., Nałecz, D., & Iwaniak, A. (1999). Database of biologically active peptide sequences. *Food/Nahrung*, 43(3), 190-195.
- Erdős, E. (1977). *The angiotensin I converting enzyme*. Paper presented at the Federation proceedings.
- Esther, C. R., Marino, E. M., Howard, T. E., Machaud, A., Corvol, P., Capecchi, M. R., & Bernstein, K. E. (1997). The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. *Journal of Clinical Investigation*, 99(10), 2375.
- Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002). Selected major risk factors and global and regional burden of disease. *The Lancet*, 360(9343), 1347-1360.
- Farag, R. S., Mahmoud, E. A., Basuny, A. M., & Ali, R. F. (2006). Influence of crude olive leaf juice on rat liver and kidney functions. *International Journal of Food Science & Technology*, 41(7), 790-798.
- Ferreira, S. H., Bartelt, D. C., & Greene, L. J. (1970). Isolation of bradykinin-potentiating peptides from *Bothrops jararaca* venom. *Biochemistry*, 9(13), 2583-2593.
- Fleming, I. (2006). Signaling by the angiotensin-converting enzyme. *Circulation Research*, 98(7), 887-896.
- Forghani, B., Ebrahimpour, A., Bakar, J., Abdul Hamid, A., Hassan, Z., & Saari, N. (2012). Enzyme Hydrolysates from *Stichopus horrens* as a New Source for Angiotensin-Converting Enzyme Inhibitory Peptides. *Evidence-Based Complementary and Alternative Medicine*, 2012.
- Fredalina, B., Ridzwan, B., Abidin, A., Kaswandi, M., Zaiton, H., Zali, I., Jais, A. (1999). Fatty acid compositions in local sea cucumber. *General Pharmacology: The Vascular System*, 33(4), 337-340.

- Fuglsang, A., Rattray, F. P., Nilsson, D., & Nyborg, N. C. (2003). Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo. *Antonie van Leeuwenhoek*, 83(1), 27-34.
- Fujita, H., Usui, H., Kurahashi, K., & Yoshikawa, M. (1995). Isolation and characterization of ovokinin, a bradykinin B agonist peptide derived from ovalbumin. *Peptides*, 16(5), 785-790.
- Fujita, H., Yamagami, T., & Ohshima, K. (2001). Effects of an ACE-inhibitory agent, katsubushi oligopeptide, in the spontaneously hypertensive rat and in borderline and mildly hypertensive subjects. *Nutrition Research*, 21(8), 1149-1158.
- Fujita, H., & Yoshikawa, M. (1999). LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. *Immunopharmacology*, 44(1), 123-127.
- Fukudome, S.-i., & Yoshikawa, M. (1993). Gluten exorphin C: a novel opioid peptide derived from wheat gluten. *FEBS letters*, 316(1), 17-19.
- Ghanbari, R., Ebrahimpour, A., Abdul-Hamid, A., Ismail, A., & Saari, N. (2012). Actinopyga lecanora hydrolysates as natural antibacterial agents. *International Journal of Molecular Sciences*, 13(12), 16796-16811.
- Gildberg, A., Arnesen, J. A., Sæther, B.-S., Rauø, J., & Stenberg, E. (2011). Angiotensin I-converting enzyme inhibitory activity in a hydrolysate of proteins from Northern shrimp and identification of two novel inhibitory tripeptides. *Process Biochemistry*, 46(11), 2205-2209.
- Gillman, M. W., Kannel, W. B., Belanger, A., & D'Agostino, R. B. (1993). Influence of heart rate on mortality among persons with hypertension: the Framingham Study. *American Heart Journal*, 125(4), 1148-1154.
- Goad, L., Garneau, F.-X., Simard, J.-L., ApSimon, J., & Girard, M. (1985). Isolation Of sterols from the sea cucumber psolusfabricii. Implications for holothurin biosynthesis. *Tetrahedron letters*, 26(29), 3513-3516.
- Gobbetti, M., Ferranti, P., Smacchi, E., Goffredi, F., & Addeo, F. (2000). Production of Angiotensin-I-Converting-Enzyme-Inhibitory Peptides in Fermented Milks Started by Lactobacillus delbrueckii subsp. bulgaricus SS1 and Lactococcus lactis subsp. cremoris FT4. *Applied and Environmental Microbiology*, 66(9), 3898-3904.
- Golik, A., Modai, D., Averbukh, Z., Sheffy, M., Shamis, A., Cohen, N., Dolev, E. (1990). Zine metabolism in patients treated with captopril versus enalapril. *Metabolism*, 39(7), 665-667.

- Golik, A., Zaidenstein, R., Dishy, V., Blatt, A., Cohen, N., Cotter, G., Weissgarten, J. (1998). Effects of captopril and enalapril on zinc metabolism in hypertensive patients. *Journal of the American College of Nutrition*, 17(1), 75-78.
- Hai-Lun, H., Xiu-Lan, C., Cai-Yun, S., Yu-Zhong, Z., & Bai-Cheng, Z. (2006). Analysis of novel angiotensin-I-converting enzyme inhibitory peptides from protease-hydrolyzed marine shrimp *Acetes chinensis*. *Journal of Peptide Science*, 12(11), 726-733.
- Hall, J. E. (2010). *Guyton and Hall Textbook of Medical Physiology: Enhanced E-book*: Elsevier Health Sciences.
- Hata, Y., Yamamoto, M., Ohni, M., Nakajima, K., Nakamura, Y., & Takano, T. (1996). A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. *The American Journal of Clinical Nutrition*, 64(5), 767-771.
- He, H.-L., Chen, X.-L., Wu, H., Sun, C.-Y., Zhang, Y.-Z., & Zhou, B.-C. (2007). High throughput and rapid screening of marine protein hydrolysates enriched in peptides with angiotensin-I-converting enzyme inhibitory activity by capillary electrophoresis. *Bioresource Technology*, 98(18), 3499-3505.
- He, H., Chen, X., Sun, C., Zhang, Y., & Gao, P. (2006). Preparation and functional evaluation of oligopeptide-enriched hydrolysate from shrimp treated with crude protease from sp. SM98011. *Bioresource Technology*, 97(3), 385-390.
- He, J., & Whelton, P. K. (1997). Epidemiology and prevention of hypertension. *Medical Clinics of North America*, 81(5), 1077-1097.
- Himaya, S., Ngo, D.-H., Ryu, B., & Kim, S.-K. (2012). An active peptide purified from gastrointestinal enzyme hydrolysate of Pacific cod skin gelatin attenuates angiotensin-1 converting enzyme (ACE) activity and cellular oxidative stress. *Food Chemistry*, 132(4), 1872-1882.
- Hing, H., Ambia, K. M., Azraul-Mumtazah, R., Hamidah, S., Sahalan, A., Shamsudin, N., Hashim, R. (2007). Effect of methanol extracts from sea cucumbers *Holothuria edulis* and *Stichopus chloronotus* on *Candida albicans*. *Microscopy and Microanalysis*, 13(S02), 270-271.
- Hodgson, E., & Levi, P. E. (2004). *A Textbook of Modern Toxicology* (Vol. 51): Wiley Online Library.
- Hong, F., Ming, L., Yi, S., Zhanxia, L., Yongquan, W., & Chi, L. (2008). The antihypertensive effect of peptides: a novel alternative to drugs *Peptides*, 29(6), 1062-1071.

- Iroyukifujita, H., Eiichiyokoyama, K., & Yoshikawa, M. (2000). Classification and Antihypertensive Activity of Angiotensin I-Converting Enzyme Inhibitory Peptides Derived from Food Proteins. *Journal of Food Science*, 65(4), 564-569.
- Jang, A., & Lee, M. (2005). Purification and identification of angiotensin converting enzyme inhibitory peptides from beef hydrolysates. *Meat Science*, 69(4), 653-661.
- Jao, C.-L., Huang, S.-L., & Hsu, K.-C. (2012). Angiotensin I-converting enzyme inhibitory peptides: Inhibition mode, bioavailability, and antihypertensive effects. *BioMedicine*, 2(4), 130-136.
- Je, J.-Y., Park, J.-Y., Jung, W.-K., Park, P.-J., & Kim, S.-K. (2005). Isolation of angiotensin I converting enzyme (ACE) inhibitor from fermented oyster sauce. *Food Chemistry*, 90(4), 809-814.
- Je, J.-Y., Park, P.-J., Byun, H.-G., Jung, W.-K., & Kim, S.-K. (2005). Angiotensin I converting enzyme (ACE) inhibitory peptide derived from the sauce of fermented blue mussel. *Bioresource Technology*, 96(14), 1624-1629.
- Jinyu, H. J. Z. Y. S. (2006). Progress of Antihypertensive Peptide Research [J]. *Food and Fermentation Industries*, 6, 024.
- Johnston, C., Iansek, R., Millari, J., McGrath, B., & Matthews, P. (1981). Vasoactive peptides and hypertension: role of angiotensin converting enzyme. *Australian and New Zealand Journal of Medicine*, 11(6), 59-63.
- Johnston, C., McGrath, B., Millar, J., & Matthews, P. (1979). Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. *The Lancet*, 314(8141), 493-496.
- Jung, E. Y., Park, S. S., Kim, J. H., Chang, U. J., Bae, S. H., Choi, J. W., & Suh, H. J. (2011). Safety study of yeast hydrolysate with below 10 kDa molecular weight in animal models. *Journal of Health Science*, 57(6), 532-539.
- Jung, W.-K., Mendis, E., Je, J.-Y., Park, P.-J., Son, B. W., Kim, H. C., Kim, S.-K. (2006). Angiotensin I-converting enzyme inhibitory peptide from yellowfin sole frame protein and its antihypertensive effect in spontaneously hypertensive rats. *Food Chemistry*, 94(1), 26-32.
- Junot, C., Gonzales, M.-F., Ezan, E., Cotton, J., Vazeux, G., Michaud, A., Corvol, P. (2001). RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide

acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. *Journal of Pharmacology and Experimental Therapeutics*, 297(2), 606-611.

Kannel, W. B. (1996). Blood pressure as a cardiovascular risk factor: prevention and treatment. *Jama*, 275(20), 1571-1576.

Katayama, K., Fuchu, H., Sakata, A., Kawahara, S., Yamauchi, K., Kawamura, Y., & Muguruma, M. (2003). Angiotensin I-converting enzyme inhibitory activities of porcine skeletal muscle proteins following enzyme digestion. *Asian Australasian Journal of Animal Sciences*, 16(3), 417-424.

Katayama, K., Mori, T., Kawahara, S., Miake, K., Kodama, Y., Sugiyama, M., Muguruma, M. (2007). Angiotensin-I Converting Enzyme Inhibitory Peptide Derived from Porcine Skeletal Muscle Myosin and Its Antihypertensive Activity in Spontaneously Hypertensive Rats. *Journal of Food Science*, 72(9), S702-S706.

Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005). Global burden of hypertension: analysis of worldwide data. *The Lancet*, 365(9455), 217-223.

Kerr, R. G., & Chen, Z. (1995). In vivo and in vitro biosynthesis of saponins in sea cucumbers. *Journal of Natural Products*, 58(2), 172-176.

Kitts, D. D., & Weiler, K. (2003). Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. *Current Pharmaceutical Design*, 9(16), 1309-1323.

Ko, S.-C., Kang, N., Kim, E.-A., Kang, M. C., Lee, S.-H., Kang, S.-M., Park, S.-J. (2012). A novel angiotensin I-converting enzyme (ACE) inhibitory peptide from a marine and its antihypertensive effect in spontaneously hypertensive rats. *Process Biochemistry*, 47(12), 2005-2011.

Kohama, Y., Matsumoto, S., Oka, H., Teramoto, T., Okabe, M., & Mimura, T. (1988). Isolation of angiotensin-converting enzyme inhibitor from tuna muscle. *Biochemical and Biophysical Research Communications*, 155(1), 332-337.

Kouno, K., Hirano, S.-i., Kuboki, H., Kasai, M., & Hatae, K. (2005). Effects of dried bonito (Katsuobushi) and captopril, an angiotensin I-converting enzyme inhibitor, on rat isolated aorta: a possible mechanism of antihypertensive action. *Bioscience, Biotechnology, and Biochemistry*, 69(5), 911-915.

Kuba, M., Tanaka, K., Tawata, S., Takeda, Y., & Yasuda, M. (2003). Angiotensin I-converting enzyme inhibitory peptides isolated from tofuyo fermented

- soybean food. *Bioscience, Biotechnology, and Biochemistry*, 67(6), 1278-1283.
- Lee, J.-E., Bae, I. Y., Lee, H. G., & Yang, C.-B. (2006). Tyr-Pro-Lys, an angiotensin I-converting enzyme inhibitory peptide derived from broccoli. *Food Chemistry*, 99(1), 143-148.
- Lee, N., Cheng, J., Enomoto, T., & Nakano, Y. (2006). One peptide derived from hen ovotransferrin as pro-drug to inhibit angiotensin converting enzyme. *Journal of Food and Drug Analysis*, 14(1), 31.
- Lee, S.-H., Qian, Z.-J., & Kim, S.-K. (2010). A novel angiotensin I converting enzyme inhibitory peptide from tuna frame protein hydrolysate and its antihypertensive effect in spontaneously hypertensive rats. *Food Chemistry*, 118(1), 96-102.
- Levy, D., Larson, M. G., Vasan, R. S., Kannel, W. B., & Ho, K. K. (1996). The progression from hypertension to congestive heart failure. *Jama*, 275(20), 1557-1562.
- Lewington, S., Clarke, R., Qizilbash, N., Peto, R., & Collins, R. (2003). Age-specific relevance of usual blood pressure to vascular mortality. *The Lancet*, 361(9366), 1391-1392.
- Li, G.-H., Qu, M.-R., Wan, J.-Z., & You, J.-M. (2007). Antihypertensive effect of rice protein hydrolysate with in vitro angiotensin I-converting enzyme inhibitory activity in spontaneously hypertensive rats. *Asia Pacific Journal of Clinical Nutrition*, 16(Suppl 1), 275-280.
- Liu, X., Zhang, M., Zhang, C., & Liu, C. (2012). Angiotensin converting enzyme (ACE) inhibitory, antihypertensive and antihyperlipidaemic activities of protein hydrolysates from. *Food Chemistry*, 134(4), 2134-2140.
- Maeno, M., Yamamoto, N., & Takano, T. (1996). Identification of an Antihypertensive Peptide from Casein Hydrolysate Produced by a Proteinase from CP790. *Journal of Dairy Science*, 79(8), 1316-1321.
- Maes, W., Van Camp, J., Vermeirssen, V., Hemeryck, M., Ketelslegers, J. M., Schrezenmeir, J., Huyghebaert, A. (2004). Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. *Regulatory Peptides*, 118(1), 105-109.
- Mamelona, J., Pelletier, É., Girard-Lalancette, K., Legault, J., Karboune, S., & Kermasha, S. (2007). Quantification of phenolic contents and antioxidant capacity of Atlantic sea cucumber. *Food Chemistry*, 104(3), 1040-1047.

- Marczak, E. D., Usui, H., Fujita, H., Yang, Y., Yokoo, M., Lipkowski, A. W., & Yoshikawa, M. (2003). New antihypertensive peptides isolated from rapeseed. *Peptides*, 24(6), 791-798.
- Matsui, T., Imamura, M., Oka, H., Osajima, K., Kimoto, K. I., Kawasaki, T., & Matsumoto, K. (2004). Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats. *Journal of Peptide Science*, 10(9), 535-545.
- Matsui, T., Li, C.-H., Tanaka, T., Maki, T., Osajima, Y., & Matsumoto, K. (2000). Depressor effect of wheat germ hydrolysate and its novel angiotensin I-converting enzyme inhibitory peptide, Ile-Val-Tyr, and the metabolism in rat and human plasma. *Biological & Pharmaceutical Bulletin*, 23(4), 427-431.
- Matsui, T., Li, C. H., & Osajima, Y. (1999). Preparation and characterization of novel bioactive peptides responsible for angiotensin I-converting enzyme inhibition from wheat germ. *Journal of Peptide Science*, 5(7), 289-297.
- Matsui, T., Tamaya, K., Seki, E., Osajima, K., Matsumoto, K., & Kawasaki, T. (2002a). Absorption of Val-Tyr with in vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects. *Biological and Pharmaceutical Bulletin*, 25(9), 1228-1230.
- Matsui, T., Tamaya, K., Seki, E., Osajima, K., Matsumoto, K., & Kawasaki, T. (2002b). Val-Tyr As A Natural Antihypertensive Dipeptide Can Be Absorbed Into The Human Circulatory Blood System. *Clinical and Experimental Pharmacology and Physiology*, 29(3), 204-208.
- Matsui, T., Yukiyoishi, A., Doi, S., Sugimoto, H., Yamada, H., & Matsumoto, K. (2002). Gastrointestinal enzyme production of bioactive peptides from royal jelly protein and their antihypertensive ability in SHR. *The Journal of Nutritional Biochemistry*, 13(2), 80-86.
- McGrath, B. P., Matthews, P. G., & Johnston, C. I. (1980). Acute changes in blood pressure and vasoactive hormones after captopril in hypertensive patients. *Clinical and Experimental Pharmacology and Physiology*, 7(5), 487-492.
- Megías, C., Yust, M. d. M., Pedroche, J., Lquari, H., Girón-Calle, J., Alaiz, M., Vioque, J. (2004). Purification of an ACE inhibitory peptide after hydrolysis of sunflower (*Helianthus annuus* L.) protein isolates. *Journal of Agricultural and Food Chemistry*, 52(7), 1928-1932.
- Meisel, H. (2004). Multifunctional peptides encrypted in milk proteins. *Biofactors*, 21(1), 55-61.

- Miguel, M., & Alexandre, A. (2006). Antihypertensive peptides derived from egg proteins. *The Journal of Nutrition*, 136(6), 1457-1460.
- Miguel, M., Alexandre, M., Ramos, M., & López-Fandiño, R. (2006). Effect of simulated gastrointestinal digestion on the antihypertensive properties of ACE-inhibitory peptides derived from ovalbumin. *Journal of Agricultural and Food Chemistry*, 54(3), 726-731.
- Miguel, M., Alonso, M. J., Salaices, M., Alexandre, A., & López-Fandiño, R. (2007). Antihypertensive, ACE-inhibitory and vasodilator properties of an egg white hydrolysate: Effect of a simulated intestinal digestion. *Food Chemistry*, 104(1), 163-168.
- Miguel, M., Contreras, M., Recio, I., & Alexandre, A. (2009). ACE-inhibitory and antihypertensive properties of a bovine casein hydrolysate. *Food Chemistry*, 112(1), 211-214.
- Miguel, M., Muguerza, B., Sánchez, E., Delgado, M., Recio, I., Ramos, M., & Alexandre, M. (2005). Changes in arterial blood pressure in hypertensive rats caused by long-term intake of milk fermented by *Enterococcus faecalis* CECT 5728. *British Journal of Nutrition*, 94(01), 36-43.
- Ming, S. (2001). Investigation on Component and Pharmacology of Sea Cucumber [J]. *Chinese Traditional Patent Medicine*, 10, 021.
- Miyoshi, S., Ishikawa, H., Kaneko, T., Fukui, F., Tanaka, H., & Maruyama, S. (1991). Structures and activity of angiotensin-converting enzyme inhibitors in an alpha-zein hydrolysate. *Agricultural and Biological Chemistry*, 55(5), 1313-1318.
- Mizuno, S., Nishimura, S., Matsuura, K., Gotou, T., & Yamamoto, N. (2004). Release of Short and Proline-Rich Antihypertensive Peptides from Casein Hydrolysate with an Protease. *Journal of Dairy Science*, 87(10), 3183-3188.
- Mojica, E.-R. E., & Merca, F. E. (2005). Biological properties of lectin from sea cucumber (*Holothuria scabra* Jäger). *J. Biol. Sci*, 5(4), 472-477.
- Mojica, E., & Merca, F. E. (2004). Lectin from the body walls of black sea cucumber (*Holothuria atra* Jäger). *Philippine Journal of Science*, 133(2), 77.
- Morita, T., Oh-hashii, A., Kasaoka, S., Ikai, M., & Kiriyama, S. (1996). Rice protein isolates produced by the two different methods lower serum cholesterol concentration in rats compared with casein. *Journal of the Science of Food and Agriculture*, 71(4), 415-424.

- Mourão, P. A., & Pereira, M. S. (1999). Searching for alternatives to heparin: sulfated fucans from marine invertebrates. *Trends in Cardiovascular Medicine*, 9(8), 225-232.
- Mullally, M. M., Meisel, H., & FitzGerald, R. J. (1997). Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine β -lactoglobulin. *FEBS letters*, 402(2), 99-101.
- Murakami, M., Tonouchi, H., Takahashi, R., Kitazawa, H., Kawai, Y., Negishi, H., & Saito, T. (2004). Structural Analysis of a New Anti-Hypertensive Peptide Isolated from a Commercial Whey Product. *Journal of Dairy Science*, 87(7), 1967-1974.
- Nagase, H., Enjyoji, K.-i., Minamiguchi, K., Kitazato, K. T., Kitazato, K., Saito, H., & Kato, H. (1995). Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III-and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. *Blood*, 85(6), 1527-1534.
- Nakagomi, K., Fujimura, A., Ebisu, H., Sakai, T., Sadakane, Y., Fujii, N., & Tanimura, T. (1998). Acein-1, a novel angiotensin-I-converting enzyme inhibitory peptide isolated from tryptic hydrolysate of human plasma. *FEBS letters*, 438(3), 255-257.
- Nakamura, Y., Yamamoto, N., Sakai, K., Okubo, A., Yamazaki, S., & Takano, T. (1995). Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. *Journal of Dairy Science*, 78(4), 777-783.
- Nakamura, Y., Yamamoto, N., Sakai, K., & Takano, T. (1995). Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. *Journal of Dairy Science*, 78(6), 1253-1257.
- Nakano, D., Ogura, K., Miyakoshi, M., Ishii, F., Kawanishi, H., Kurumazuka, D., Moriguchi, S. (2006). Antihypertensive effect of angiotensin I-converting enzyme inhibitory peptides from a sesame protein hydrolysate in spontaneously hypertensive rats. *Bioscience, Biotechnology, and Biochemistry*, 70(5), 1118-1126.
- Nakashima, Y., Arihara, K., Sasaki, A., Mio, H., Ishikawa, S., & Itoh, M. (2002). Antihypertensive activities of peptides derived from porcine skeletal muscle myosin in spontaneously hypertensive rats. *Journal of Food Science*, 67(1), 434-437.

- Natesh, R., Schwager, S. L., Sturrock, E. D., & Acharya, K. R. (2003). Crystal structure of the human angiotensin-converting enzyme–lisinopril complex. *Nature*, 421(6922), 551-554.
- Neaton, J. D., & Wentworth, D. (1992). Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease overall findings and differences by age for 316099 white men. *Archives of Internal Medicine*, 152(1), 56-64.
- Norris, R., & FitzGerald, R. J. (2013). Antihypertensive peptides from food proteins. *Bioactive food peptides in health and disease. Rijeka, Croatia: Intech Prepress*. p, 45-72.
- Oecd. (1994). *OECD Guidelines for the Testing of Chemicals*: Organization for Economic.
- Ohara, I., Tabuchi, R., & Onai, K. (2000). Effects of modified rice bran on serum lipids and taste preference in streptozotocin-induced diabetic rats. *Nutrition Research*, 20(1), 59-68.
- Ondetti, M., & Cushman, D. (1982). Enzymes of the renin-angiotensin system and their inhibitors. *Annual Review of Biochemistry*, 51(1), 283-308.
- Ondetti, M., Rubin, B., & Cushman, D. (1977). Dr. Sameh Shaheen MD, FESC. *Science*, 196(4288), 441-444.
- Ondetti, M. A., Williams, N. J., Sabo, E., Pluscec, J., Weaver, E. R., & Kocy, O. (1971). Angiotensin-converting enzyme inhibitors from the venom of *Bothrops jararaca*. Isolation, elucidation of structure, and synthesis. *Biochemistry*, 10(22), 4033-4039.
- Ono, S., Hosokawa, M., Miyashita, K., & Takahashi, K. (2003). Isolation of Peptides with Angiotensin I-converting Enzyme Inhibitory Effect Derived from Hydrolysate of Upstream Chum Salmon Muscle. *Journal of Food Science*, 68(5), 1611-1614.
- Organization, W. H. (2002). The World health report: 2002: Reducing the risks, promoting healthy life.
- Oshima, G., Shimabukuro, H., & Nagasawa, K. (1979). Peptide inhibitors of angiotensin I-converting enzyme in digests of gelatin by bacterial collagenase. *Biochimica et Biophysica Acta (BBA)-Enzymology*, 566(1), 128-137.

- Pacheco, R., Vicente, C., Zancan, P., & Mourão, P. (2000). Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. *Blood Coagulation & Fibrinolysis*, *11*(6), 563-573.
- Paliwal, A., Gurjar, R., & Sharma, H. (2009). Analysis of liver enzymes in albino rat under stress of λ -cyhalothrin and nuvan toxicity. *Biol Med*, *1*(2), 70-73.
- Park, C. B., Lee, J. H., Park, I. Y., Kim, M. S., & Kim, S. C. (1997). A novel antimicrobial peptide from the loach. *FEBS letters*, *411*(2), 173-178.
- Patchett, A., Harris, E., Tristram, E., Wyvratt, M., Wu, M., Taub, D., Payne, L. (1980). A new class of angiotensin-converting enzyme inhibitors.
- Patel, C., Dadhaniya, P., Hingorani, L., & Soni, M. (2008). Safety assessment of pomegranate fruit extract: acute and subchronic toxicity studies. *Food and Chemical Toxicology*, *46*(8), 2728-2735.
- Peña-Ramos, E., & Xiong, Y. (2002). Antioxidant activity of soy protein hydrolysates in a liposomal system. *Journal of Food Science*, *67*(8), 2952-2956.
- Pfeuffer, M., & Schrezenmeir, J. (2000). Bioactive substances in milk with properties decreasing risk of cardiovascular diseases. *British Journal of Nutrition*, *84*(S1), 155-159.
- Phelan, M., & Kerins, D. (2011). The potential role of milk-derived peptides in cardiovascular disease. *Food & Function*, *2*(3-4), 153-167.
- Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Roccella, E. J. (2005). Recommendations for blood pressure measurement in humans and experimental animals part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Hypertension*, *45*(1), 142-161.
- Poli, G., Albano, E., & Dianzani, M. U. (1987). The role of lipid peroxidation in liver damage. *Chemistry and Physics of Lipids*, *45*(2), 117-142.
- Pozo-Bayón, M., Alcaíde, J. M., Polo, M. C., & Pueyo, E. (2007). Angiotensin I-converting enzyme inhibitory compounds in white and red wines. *Food Chemistry*, *100*(1), 43-47.
- Qian, Z.-J., Je, J.-Y., & Kim, S.-K. (2007). Antihypertensive effect of angiotensin I converting enzyme-inhibitory peptide from hydrolysates of bigeye tuna dark

- muscle, *Thunnus obesus*. *Journal of Agricultural and Food Chemistry*, 55(21), 8398-8403.
- Qu, W., Ma, H., Pan, Z., Luo, L., Wang, Z., & He, R. (2010). Preparation and antihypertensive activity of peptides from. *Food Chemistry*, 123(1), 14-20.
- Rafiuddin Ahmed, M., Venkateshwarlu, U., & Jayakumar, R. (2004). Multilayered peptide incorporated collagen tubules for peripheral nerve repair. *Biomaterials*, 25(13), 2585-2594.
- Rahman, M., Siddiqui, M. K., & Jamil, K. (2001). Effects of Vepacide (*Azadirachta indica*) on asp artate and al anine aminotransferase profiles in a subchronic study with rats. *Human & Experimental Toxicology*, 20(5), 243-249.
- Rampal, L., Rampal, S., Azhar, M., & Rahman, A. R. (2008). Prevalence, awareness, treatment and control of hypertension in Malaysia: a national study of 16,440 subjects. *Public Health*, 122(1), 11-18.
- Rasmussen, S., Leth, A., Ibsen, H., Nielsen, M. D., Nielsen, F., & Giese, J. (1985). Converting enzyme inhibition in mild and moderate essential hypertension: i. acute effects on blood pressure, the renin-angiotensin system and blood bradykinin after a single dose of captopril. *Acta medica Scandinavica*, 218(5), 435-442.
- Reiner, Ž. (2009). How to improve cardiovascular diseases prevention in Europe? *Nutrition, Metabolism and Cardiovascular Diseases*, 19(7), 451-454.
- Ridzwan, B., Kaswandi, M., Azman, Y., & Fuad, M. (1995). Screening for antibacterial agents in three species of sea cucumbers from coastal areas of Sabah. *General Pharmacology: The Vascular System*, 26(7), 1539-1543.
- Riordan, J. F. (2003). Angiotensin-I-converting enzyme and its relatives. *Genome Biol*, 4(8), 225.
- Roginsky, A., Singh, B., Ding, X.-Z., Collin, P., Woodward, C., Talamonti, M., Adrian, T. (2004). Frondanol from the sea cucumber, *cucumaria frondosa* induces cell cycle arrest and apoptosis in pancreatic cancer cells. *Pancreas*, 29(4), 335.
- Saiga, A., Okumura, T., Makihara, T., Katsuta, S., Shimizu, T., Yamada, R., & Nishimura, T. (2003). Angiotensin I-converting enzyme inhibitory peptides in a hydrolyzed chicken breast muscle extract. *Journal of Agricultural and Food Chemistry*, 51(6), 1741-1745.

- Saito, T., Nakamura, T., Kitazawa, H., Kawai, Y., & Itoh, T. (2000). Isolation and structural analysis of antihypertensive peptides that exist naturally in Gouda cheese. *Journal of Dairy Science*, 83(7), 1434-1440.
- Saito, Y., Wanezaki Nakamura, K., Kawato, A., & Imayasu, S. (1994). Structure and activity of angiotensin I converting enzyme inhibitory peptides from sake and sake lees. *Biosciences Biotechnology and Biochemistry*, 58(10), 1767-1771.
- Sato, M., Hosokawa, T., Yamaguchi, T., Nakano, T., Muramoto, K., Kahara, T., Nakano, T. (2002). Angiotensin I-converting enzyme inhibitory peptides derived from wakame (*Undaria pinnatifida*) and their antihypertensive effect in spontaneously hypertensive rats. *Journal of Agricultural and Food Chemistry*, 50(21), 6245-6252.
- Sato, M., Oba, T., Yamaguchi, T., Nakano, T., Kahara, T., Funayama, K., & Kobayashi, A. (2002). Antihypertensive effects of hydrolysates of wakame (*Undaria pinnatifida*) and their angiotensin-I-converting enzyme inhibitory activity. *Annals of Nutrition and Metabolism*, 46(6), 259-267.
- Segall, L., Covic, A., & Goldsmith, D. J. (2007). Direct renin inhibitors: the dawn of a new era, or just a variation on a theme. *Nephrology Dialysis Transplantation*, 22(9), 2435-2439.
- Seki, E., Osajima, K., Matsufuji, H., Matsui, T., & Osajima, Y. (1995). Val-Tyr, and angiotensin I converting enzyme inhibitor from sardines that have resistance to gastrointestinal proteases. *Journal of the Agricultural Chemical Society of Japan (Japan)*.
- Sheih, I., Fang, T. J., & Wu, T.-K. (2009). Isolation and characterisation of a novel angiotensin I-converting enzyme (ACE) inhibitory peptide from the algae protein waste. *Food Chemistry*, 115(1), 279-284.
- Shiell, G. (2004). Field observations of juvenile sea cucumbers. *SPC Beche-de-mer Inf. Bull*, 20, 6-11.
- Shiozaki, K., Shiozaki, M., Masuda, J., Yamauchi, A., Ohwada, S., Nakano, T., Sato, M. (2010). Identification of oyster-derived hypotensive peptide acting as angiotensin-I-converting enzyme inhibitor. *Fisheries Science*, 76(5), 865-872.
- Si, D., Wang, Y., Zhou, Y.-H., Guo, Y., Wang, J., Zhou, H., Fawcett, J. P. (2009). Mechanism of CYP2C9 inhibition by flavones and flavonols. *Drug Metabolism and Disposition*, 37(3), 629-634.
- Singh, R., Suh, I., Singh, V., Chaithiraphan, S., Laothavorn, P., Sy, R., Tomlinson, B. (2000). Hypertension and stroke in Asia: prevalence, control and strategies in

- developing countries for prevention. *Journal of Human Hypertension*, 14(10-11), 749-764.
- Sipola, M., Finckenberg, P., Vapaatalo, H., Pihlanto-Leppälä, A., Korhonen, H., Korpela, R., & Nurminen, M.-L. (2002). α -Lactorphin and β -lactorphin improve arterial function in spontaneously hypertensive rats. *Life Sciences*, 71(11), 1245-1253.
- Smacchi, E., & Gobbetti, M. (1998). Peptides from several Italian cheeses inhibitory to proteolytic enzymes of lactic acid bacteria, *Pseudomonas fluorescens* ATCC 948 and to the angiotensin I-converting enzyme. *Enzyme and Microbial Technology*, 22(8), 687-694.
- Subissi, A., Criscuoli, M., Sardelli, G., Guelfi, M., & Giachetti, A. (1992). Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors. *Journal of Cardiovascular Pharmacology*, 20(1), 139-146.
- Suetsuna, K. (1998). Isolation and characterization of angiotensin I-converting enzyme inhibitor dipeptides derived from (garlic). *The Journal of Nutritional Biochemistry*, 9(7), 415-419.
- Suetsuna, K., Maekawa, K., & Chen, J.-R. (2004). Antihypertensive effects of wakamenpeptide on blood pressure in spontaneously hypertensive rats. *The Journal of Nutritional Biochemistry*, 15(5), 267-272.
- Suetsuna, K., & Nakano, T. (2000). Identification of an antihypertensive peptide from peptic digest of wakame. *The Journal of Nutritional Biochemistry*, 11(9), 450-454.
- Sugawara, T., Zaima, N., Yamamoto, A., Sakai, S., Noguchi, R., & Hirata, T. (2006). Isolation of sphingoid bases of sea cucumber cerebroside and their cytotoxicity against human colon cancer cells. *Bioscience, Biotechnology, and Biochemistry*, 70(12), 2906-2912.
- Takahashi, M., Moriguchi, S., Ikeno, M., Kono, S., Ohata, K., Usui, H., Yoshikawa, M. (1996). Studies on the ileum-contracting mechanisms and identification as a complement C3a receptor agonist of oryzatensin, a bioactive peptide derived from rice albumin. *Peptides*, 17(1), 5-12.
- Teo, S. K., Stirling, D. I., Thomas, S. D., Evans, M. G., & Khetani, V. D. (2003). A 90-Day Oral Gavage Toxicity Study of d-Methylphenidate and d, l-Methylphenidate in Beagle Dogs. *International Journal of Toxicology*, 22(3), 215-226.

- Tian, F., Zhang, X., Tong, Y., Yi, Y., Zhang, S., Li, L., Ding, J. (2005). Research paper, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. *Cancer Biology & Therapy*, 4(8), 874-882.
- Tokunaga, K.-h., Yoshida, C., Suzuki, K.-m., Maruyama, H., Futamura, Y., Araki, Y., & Mishima, S. (2004). Antihypertensive effect of peptides from royal jelly in spontaneously hypertensive rats. *Biological and Pharmaceutical Bulletin*, 27(2), 189-192.
- Tsai, J.-S., Chen, J.-L., & Pan, B. S. (2008). ACE-inhibitory peptides identified from the muscle protein hydrolysate of hard clam. *Process Biochemistry*, 43(7), 743-747.
- Ueshima, H., Zhang, X., & Choudhury, S. (1999). Epidemiology of hypertension in China and Japan. *Journal of Human Hypertension*, 14(10-11), 765-769.
- van Esch, J. H., Tom, B., Dive, V., Batenburg, W. W., Georgiadis, D., Yiotakis, A., Danser, A. J. (2005). Selective Angiotensin-Converting Enzyme C-Domain Inhibition Is Sufficient to Prevent Angiotensin I-Induced Vasoconstriction. *Hypertension*, 45(1), 120-125.
- Vanhoof, G., Goossens, F., De Meester, I., Hendriks, D., & Scharpe, S. (1995). Proline motifs in peptides and their biological processing. *The FASEB Journal*, 9(9), 736-744.
- Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C., O'Donnell, C. J., Kannel, W. B., & Levy, D. (2001). Impact of high-normal blood pressure on the risk of cardiovascular disease. *New England Journal of Medicine*, 345(18), 1291-1297.
- Venugopal, D., Klapper, D., Srouji, A. H., Bhonsle, J. B., Borschel, R., Mueller, A., Hicks, R. P. (2010). Novel antimicrobial peptides that exhibit activity against select agents and other drug resistant bacteria. *Bioorganic & Medicinal Chemistry*, 18(14), 5137-5147.
- Vermeirssen, V., Van Camp, J., Decroos, K., Van Wijmelbeke, L., & Verstraete, W. (2003). The impact of fermentation and in vitro digestion on the formation of angiotensin-I-converting enzyme inhibitory activity from pea and whey protein. *Journal of Dairy Science*, 86(2), 429-438.
- Vieira, R. P., Mulloy, B., & Mourao, P. (1991). Structure of a fucose-branched chondroitin sulfate from sea cucumber. Evidence for the presence of 3-O-sulfo-beta-D-glucuronosyl residues. *Journal of Biological Chemistry*, 266(21), 13530-13536.

- Wako, Y., Ishikawa, S., & Muramoto, K. (1996). Angiotensin I-converting enzyme inhibitors in autolysates of squid liver and mantle muscle. *Bioscience, Biotechnology, and Biochemistry*, 60(8), 1353-1355.
- Wang, J., Hu, J., Cui, J., Bai, X., Du, Y., Miyaguchi, Y., & Lin, B. (2008). Purification and identification of a ACE inhibitory peptide from oyster proteins hydrolysate and the antihypertensive effect of hydrolysate in spontaneously hypertensive rats. *Food Chemistry*, 111(2), 302-308.
- Wang, X., Wang, L., Cheng, X., Zhou, J., Tang, X., & Mao, X.-Y. (2012). Hypertension-attenuating effect of whey protein hydrolysate on spontaneously hypertensive rats. *Food Chemistry*, 134(1), 122-126.
- Webb, K. E. (1990). Intestinal absorption of protein hydrolysis products: a review. *Journal of Animal Science*, 68(9), 3011-3022.
- Wei, L., Clauser, E., Alhenc-Gelas, F., & Corvol, P. (1992). The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. *Journal of Biological Chemistry*, 267(19), 13398-13405.
- Wen, J., Hu, C., & Fan, S. (2010). Chemical composition and nutritional quality of sea cucumbers. *Journal of the Science of Food and Agriculture*, 90(14), 2469-2474.
- Whelton, P. K. (1994). Epidemiology of hypertension. *The Lancet*, 344(8915), 101-106.
- Wu, H., He, H.-L., Chen, X.-L., Sun, C.-Y., Zhang, Y.-Z., & Zhou, B.-C. (2008). Purification and identification of novel angiotensin-I-converting enzyme inhibitory peptides from shark meat hydrolysate. *Process Biochemistry*, 43(4), 457-461.
- Wu, J., & Ding, X. (2002). Characterization of inhibition and stability of soy-protein-derived angiotensin I-converting enzyme inhibitory peptides. *Food Research International*, 35(4), 367-375.
- Yamamoto, N. (1997). Antihypertensive peptides derived from food proteins. *Peptide Science*, 43(2), 129-134.
- Yamamoto, N., Maeno, M., & Takano, T. (1999). Purification and Characterization of an Antihypertensive Peptide from a Yogurt-Like Product Fermented by CPN4. *Journal of Dairy Science*, 82(7), 1388-1393.

- Yan, R., De-Guang, W., Xian-ming, L., Lu, C., Tian-e, Z., & Jin-Lin, G. (2011). Isolation and characterization of angiotensin I-converting enzyme inhibitor peptides derived from porcine hemoglobin. *Scientific Research and Essays*, 6(30), 6262-6269.
- Yang, Y., Marczak, E. D., Yokoo, M., Usui, H., & Yoshikawa, M. (2003). Isolation and antihypertensive effect of angiotensin I-converting enzyme (ACE) inhibitory peptides from spinach Rubisco. *Journal of Agricultural and Food Chemistry*, 51(17), 4897-4902.
- Yano, S., Suzuki, K., & Funatsu, G. (1996). Isolation from alpha-zein of thermolysin peptides with angiotensin I-converting enzyme inhibitory activity. *Bioscience, Biotechnology, and Biochemistry*, 60(4), 661-663.
- Yoshikawa, M., Fujita, H., Matoba, N., Takenaka, Y., Yamamoto, T., Yamauchi, R., Takahata, K. (2000). Bioactive peptides derived from food proteins preventing lifestyle-related diseases. *Biofactors*, 12(1), 143-146.
- Yu, Y., Hu, J., Miyaguchi, Y., Bai, X., Du, Y., & Lin, B. (2006). Isolation and characterization of angiotensin I-converting enzyme inhibitory peptides derived from porcine hemoglobin. *Peptides*, 27(11), 2950-2956.
- Zhao, Y., Li, B., Liu, Z., Dong, S., Zhao, X., & Zeng, M. (2007). Antihypertensive effect and purification of an ACE inhibitory peptide from sea cucumber gelatin hydrolysate. *Process Biochemistry*, 42(12), 1586-1591.
- Zhao, Y., Li, B., Dong, S., Liu, Z., Zhao, X., Wang, J., & Zeng, M. (2009). A novel ACE inhibitory peptide isolated from hydrolysate. *Peptides*, 30(6), 1028-1033.
- Zhong, F., Zhang, X., Ma, J., & Shoemaker, C. F. (2007). Fractionation and identification of a novel hypocholesterolemic peptide derived from soy protein Alcalase hydrolysates. *Food Research International*, 40(6), 756-762.
- Zhong, Y., Khan, M. A., & Shahidi, F. (2007). Compositional characteristics and antioxidant properties of fresh and processed sea cucumber (*Cucumaria frondosa*). *Journal of Agricultural and Food Chemistry*, 55(4), 1188-1192.